STOCKHOLM, Oct. 15, 2018 /PRNewswire/ -- IRRAS AB (Nasdaq
First North Premier: IRRAS) announced today that it has expanded
its product development and manufacturing capabilities by hiring
key top talents to the organization. Mr. Adam Sampson will lead production and
manufacturing as Vice President of Product Excellence, and Mr.
Dino De Cicco will serve as Senior
Director, Product Development, in the
United States. Collectively, Mr. Sampson and Mr. De Cicco
have over 40 years of relevant medical device experience and have
significant expertise in developing and launching innovative
products across the globe. Prior to joining IRRAS, Mr. Sampson was
recently Global Vice President of Engineering & Product
Development at Fluidmaster and previously Principal Product Manager
with Sun Microsystems, and Mr. De Cicco was Senior R&D Manager
at Philips and previously Director of Engineering at Nexgen Medical
Systems.
"We are very excited to have successful and experienced medical
device professionals such as Adam and Dino joining IRRAS. They are
tremendous assets for our company as we continue to recruit top
talents and enhance both the technical and cultural fundamentals of
our company," said Kleanthis G.
Xanthopoulos, Ph.D., President and CEO of IRRAS. "We look
forward to harnessing their expertise as we prepare to launch
IRRAflow in the U.S later this year."
For more information, please contact:
US
Kleanthis G.
Xanthopoulos, Ph.D.
President & CEO
info@irras.com
Europe
Fredrik
Alpsten
CFO and Deputy CEO
+46-706-67-31-06
fredrik.alpsten@irras.com
About IRRAS
IRRAS AB (Nasdaq First North Premier: IRRAS) is a
publicly-traded, commercial-stage medical technology company
focused on developing and commercializing innovative solutions for
brain surgery. The company's initial product,
IRRAflow®, addresses the complications associated with
the current methods of managing intracranial fluid by using a dual
lumen catheter that combines active irrigation with ongoing fluid
drainage. IRRAflow received FDA clearance in July 2018.
Regularly during treatment, the IRRAflow catheter is
automatically flushed to prevent common catheter occlusions from
forming. Because IRRAflow is a completely closed system, it
is designed to reduce the documented infection risk of
these procedures. Additionally, IRRAflow incorporates ICP
monitoring and uses a proprietary software to regulate treatment
based on desired pressure levels.
With its unique product portfolio, protected by property patents
and patent applications, IRRAS is well positioned to establish a
leadership position in the medical device market. IRRAS maintains
its headquarters in Stockholm,
Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier. Wildeco
is certified adviser of the company.
The information was released for public disclosure, through the
agency of the contact person above, on October 15, 2018 at 8.00
a.m. (CET).
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/irras/r/irras-expands-its-product-development-and-manufacturing-team-in-the-u-s--with-the-hiring-of-key-tale,c2644242
The following files are available for download:
http://mb.cision.com/Main/16550/2644242/926436.pdf
|
Press release
(PDF)
|